Enliven Therapeutics, Inc. (ELVN) — SC 13D/A Filings

SC 13D/A Filings (6)

• 5AM Ventures VI Amends Enliven Therapeutics Stake — Jul 29, 2024 Risk: medium
  On July 29, 2024, 5AM Ventures VI, L.P. filed an amendment (No. 5) to its Schedule 13D regarding Enliven Therapeutics, Inc. The filing indicates a change in ben
• OrbiMed Amends Stake in Enliven Therapeutics — May 20, 2024 Risk: medium
  OrbiMed Advisors LLC, along with affiliated entities, has amended its Schedule 13D filing regarding Enliven Therapeutics, Inc. The filing, dated May 20, 2024, i
• 5AM Ventures VI amends Enliven Therapeutics stake — Apr 15, 2024 Risk: medium
  On April 15, 2024, 5AM Ventures VI, L.P. filed an amendment (No. 4) to its Schedule 13D regarding Enliven Therapeutics, Inc. The filing indicates a change in be
• OrbiMed Amends Enliven Therapeutics Stake — Apr 4, 2024 Risk: medium
  On April 4, 2024, OrbiMed Advisors LLC, along with affiliated entities, filed an amendment to their Schedule 13D concerning Enliven Therapeutics, Inc. The filin
• 5AM Ventures Amends Enliven Therapeutics Stake — Feb 16, 2024 Risk: low
  5AM Ventures VI, L.P. and its affiliated entities, including 5AM Opportunities I, L.P. and 5AM Partners VI, LLC, filed an Amendment No. 3 to their Schedule 13D
• 5AM Ventures Reduces Enliven Therapeutics Stake to 16.7% — Feb 2, 2024
  5AM Ventures VI, L.P. and its affiliated entities (the "5AM Group") filed an amended Schedule 13D/A on February 2, 2024, updating their beneficial ownership in

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX